


~~IAP4 Rec'd 1/6/06~~ 04 JAN 2006 PET



PATENT  
Customer No. 22,852  
Attorney Docket No. 06267.0127

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:	)	
	)	
Jukka GYNTER et al.	)	Group Art Unit: To Be Assigned
	)	
Application No.: 10/541,387	)	Examiner: To Be Assigned
	)	
Filed: July 1, 2005	)	
	)	
For: COMPOUNDS HAVING PROLYL	)	Confirmation No.: To Be Assigned
OLIGOPEPTIDASE INHIBITORY	)	
ACTIVITY	)	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.97(b)**

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents on the attached listing. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed foreign and non-patent literature documents are attached.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do

not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.


If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,


FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: January 4, 2006

By: \_\_\_\_\_

  
Steven J. Scott  
Reg. No. 43,911

IDS Form PTO/SB/08: Substitute for form 1449A/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/541,387
		Filing Date	July 1, 2005
		First Named Inventor	Jukka GYNTHNER
		Art Unit	Unassigned
		Examiner Name	Unassigned
Sheet	1	of	2
		Attorney Docket Number	06267.0127



U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS					
Examiner Initials	Cite No. <sup>1</sup>	Document Number	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

FOREIGN PATENT DOCUMENTS						
Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation
		Sherwin Wilk, "Minireview Prolyl Endopeptidase," Life Sciences, Vol. 33, pp. 2149-2157, 1983	
		Rhonda O'Leary et al., "Thyrotropin-Releasing Hormone," Journal of Neurochemistry, Vol. 65, No. 3, pp. 953-963, 1995	
		Tadashi Yoshimoto et al., "Specific Inhibitors for Prolyl Endopeptidase and Their Anti-Amnesic Effect," J. Pharmacobio-Dyn., Vol. 10, pp. 730-735, 1987	
		Neil W. Kowall et al., "An <i>in vivo</i> model for the neurodegenerative effects of $\beta$ amyloid and protection by substance P," Proc. Natl. Acad. Sci., Vol. 88, pp. 7247-7251, 1991	
		Daniel Nöteberg et al., "New Proline Mimetics: Synthesis of Thrombin Inhibitors Incorporating Cyclopentane- and Cyclopentenedicarboxylic Acid Templates in the P2 Position. Binding Conformation Investigated by X-ray Crystallography," J. Med. Chem., Vol. 43, pp. 1705-1713, 2000	
		Eric Beausoleil et al., "5- <i>tert</i> -Butylproline," J. Org. Chem., Vol. 61, pp. 9447-9454, 1996	
		Iván Collado et al., "Stereoselective Addition of Grignard-Derived Organocopper Reagents to <i>N</i> -Acyliminium Ions: Synthesis of Enantiopure 5- and 4,5-substituted Prolinates," J. Org. Chem., Vol. 60, pp. 5011-5015, 1995	
		Herman Gershon et al., "Amino Acid Analogs. I. Analogs of the Glutamic Acid, Proline Interconversion. Part I. <i>w</i> -Methyl- and <i>w</i> -Phenylketoglutamic Acids and 5-Methyl- and 5-Phenylprolines," Amino Acid Analogs. I, Vol. 26, pp. 2347-2350, 1961	
		Teresa L. Ho et al., "An Asymmetric Synthesis of <i>cis</i> -5-Alkylproline Derivatives," Vol. 51, No. 13, pp. 2405-2408, 1986	
		Houda H. Ibrahim et al., "Synthesis of Enantiopure $\alpha$ -Oxo $\alpha$ -Amino Esters and Prolines via Acylation of <i>N</i> -(Phenylfluorenyl)glutamate Enolates," J. Org. Chem., Vol. 58, pp. 6438-6441, 1993	
		C. G. Overberger et al., "Synthesis and Resolution of <i>cis</i> - and <i>trans</i> -5-Methylproline," Macromolecules, Vol. 5, No. 4, pp. 368-372, 1972	
		Stephen G. Pyne et al., "Asymmetric Synthesis of Proline Derivatives from (2 <i>R</i> ) and (2 <i>S</i> )-2- <i>tert</i> -Butyl-3-Benzoyl-4-Methyleneoxazolidin-5-one," Tetrahedron, Vol. 51, pp. 5157-5169, 1995	
		Yasushi Sanno, "Studies on the Active Compounds of <i>Digena simplex</i> Ag. and Related Compounds. LXII. Syntheses of Proline Derivates by the Cyclization of $\alpha$ -Aminoketones," Yakugaku Zasshi, Vol. 79, No. 10, pp. 1113-1123, 1958	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

(Use as many sheets as necessary)

2

<b>Application Number</b>	10/541,387
<b>Filing Date</b>	July 1, 2005
<b>First Named Inventor</b>	Jukka GYNTER
<b>Art Unit</b>	Unassigned
<b>Examiner Name</b>	Unassigned
<b>Attorney Docket Number</b>	06267.0127

[illegible]Date  
Considered

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.